These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 15673542)
1. Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudy. Ray KK; Morrow DA; Gibson CM; Murphy S; Antman EM; Braunwald E Eur Heart J; 2005 Mar; 26(5):440-6. PubMed ID: 15673542 [TBL] [Abstract][Full Text] [Related]
2. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. Mega JL; Morrow DA; De Lemos JA; Sabatine MS; Murphy SA; Rifai N; Gibson CM; Antman EM; Braunwald E J Am Coll Cardiol; 2004 Jul; 44(2):335-9. PubMed ID: 15261928 [TBL] [Abstract][Full Text] [Related]
3. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. Gibson CM; Murphy SA; Montalescot G; Morrow DA; Ardissino D; Cohen M; Gulba DC; Kracoff OH; Lewis BS; Roguin N; Antman EM; Braunwald E; J Am Coll Cardiol; 2007 Jun; 49(23):2238-46. PubMed ID: 17560287 [TBL] [Abstract][Full Text] [Related]
4. Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) trial. Morrow DA; Antman EM; Murphy SA; Qin J; Ruda M; Guneri S; Jacob AJ; Budaj A; Braunwald E; Am Heart J; 2007 Dec; 154(6):1078-84, 1084.e1. PubMed ID: 18035078 [TBL] [Abstract][Full Text] [Related]
5. Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis. Giraldez RR; Nicolau JC; Corbalan R; Gurfinkel EP; Juarez U; Lopez-Sendon J; Parkhomenko A; Molhoek P; Mohanavelu S; Morrow DA; Antman EM Eur Heart J; 2007 Jul; 28(13):1566-73. PubMed ID: 17562672 [TBL] [Abstract][Full Text] [Related]
6. ExTRACT-TIMI 25 trial: clarifying the role of enoxaparin in patients with ST-elevation myocardial infarction receiving fibrinolysis. Gabriel RS; White HD Expert Rev Cardiovasc Ther; 2007 Sep; 5(5):851-7. PubMed ID: 17867915 [TBL] [Abstract][Full Text] [Related]
7. A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG study. Scirica BM; Morrow DA; Sadowski Z; Ruda M; Nicolau JC; Giugliano RP; Wiviott SD; Sabatine MS; Shui A; Antman EM; Braunwald E Eur Heart J; 2007 Sep; 28(17):2070-6. PubMed ID: 17600039 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel. Sabatine MS; Morrow DA; Dalby A; Pfisterer M; Duris T; Lopez-Sendon J; Murphy SA; Gao R; Antman EM; Braunwald E; J Am Coll Cardiol; 2007 Jun; 49(23):2256-63. PubMed ID: 17560290 [TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of enoxaparin in acute ST-segment elevation myocardial infarction: the ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction 25) study. Marcoff L; Zhang Z; Zhang W; Ewen E; Jurkovitz C; Leguet P; Kolm P; Weintraub WS J Am Coll Cardiol; 2009 Sep; 54(14):1271-9. PubMed ID: 19778669 [TBL] [Abstract][Full Text] [Related]
10. Is transport with platelet GP IIb/IIIa inhibition for primary percutaneous coronary intervention more efficient than on-site thrombolysis in patients with STEMI admitted to community hospitals? Randomised study. Early results. Dobrzycki S; Mezyński G; Kralisz P; Prokopczuk P; Nowak K; Kochman W; Zuk J; Bachórzewska-Gajewska H; Sawicki Z; Poniatowski B; Korecki J; Musiał WJ Kardiol Pol; 2006 Aug; 64(8):793-9; discussion 800-1. PubMed ID: 16981054 [TBL] [Abstract][Full Text] [Related]
11. Facilitated angioplasty with combo therapy among patients with ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. De Luca G; Marino P Am J Emerg Med; 2009 Jul; 27(6):683-90. PubMed ID: 19751625 [TBL] [Abstract][Full Text] [Related]
13. Transfer with GP IIb/IIIa inhibitor tirofiban for primary percutaneous coronary intervention vs. on-site thrombolysis in patients with ST-elevation myocardial infarction (STEMI): a randomized open-label study for patients admitted to community hospitals. Dobrzycki S; Kralisz P; Nowak K; Prokopczuk P; Kochman W; Korecki J; Poniatowski B; Zuk J; Sitniewska E; Bachorzewska-Gajewska H; Sienkiewicz J; Musial WJ Eur Heart J; 2007 Oct; 28(20):2438-48. PubMed ID: 17884846 [TBL] [Abstract][Full Text] [Related]
14. Global outcomes of ST-elevation myocardial infarction: comparisons of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) registry and trial. Steinberg BA; Moghbeli N; Buros J; Ruda M; Parkhomenko A; Raju BS; García-Castillo A; Janion M; Nicolau JC; Fox KA; Morrow DA; Gibson CM; Antman EM Am Heart J; 2007 Jul; 154(1):54-61. PubMed ID: 17584551 [TBL] [Abstract][Full Text] [Related]
15. Association between thrombolysis in myocardial infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: observations from the randomized trial to evaluate the relative PROTECTion against post-PCI microvascular dysfunction and post-PCI ischemia among antiplatelet and antithrombotic agents-Thrombolysis In Myocardial Infarction 30 (PROTECT-TIMI 30). Gibson CM; Kirtane AJ; Morrow DA; Palabrica TM; Murphy SA; Stone PH; Scirica BM; Jennings LK; Herrmann HC; Cohen DJ; McCabe CH; Braunwald E; Am Heart J; 2006 Oct; 152(4):756-61. PubMed ID: 16996854 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of enoxaparin compared with unfractionated heparin in the pharmacoinvasive management of acute ST-segment elevation myocardial infarction: Insights from the TRANSFER-AMI trial. Lavi S; Cantor WJ; Casanova A; Tan MK; Yan AT; Džavík V; Fitchett D; Cohen EA; Borgundvaag B; Heffernan M; Ducas J; Goodman SG Am Heart J; 2012 Feb; 163(2):176-81.e2. PubMed ID: 22305834 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Murphy SA; Gibson CM; Morrow DA; Van de Werf F; Menown IB; Goodman SG; Mahaffey KW; Cohen M; McCabe CH; Antman EM; Braunwald E Eur Heart J; 2007 Sep; 28(17):2077-86. PubMed ID: 17600038 [TBL] [Abstract][Full Text] [Related]
18. A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes. Califf RM; Petersen JL; Hasselblad V; Mahaffey KW; Ferguson JJ Am Heart J; 2005 Apr; 149(4 Suppl):S91-9. PubMed ID: 16124953 [TBL] [Abstract][Full Text] [Related]
19. Sequential risk stratification using TIMI risk score and TIMI flow grade among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction. Karmpaliotis D; Turakhia MP; Kirtane AJ; Murphy SA; Kosmidou I; Morrow DA; Giugliano RP; Cannon CP; Antman EM; Braunwald E; Gibson CM; Am J Cardiol; 2004 Nov; 94(9):1113-7. PubMed ID: 15518603 [TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of combination glycoprotein IIbIIIa inhibitors and reduced-dose thrombolytic therapy-facilitated percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized clinical trials. Sinno MC; Khanal S; Al-Mallah MH; Arida M; Weaver WD Am Heart J; 2007 Apr; 153(4):579-86. PubMed ID: 17383297 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]